CAS Number: 85650-56-2
Therapeutic Category
Bipolar-Disorder
Anti-Schizophrenic
Central Nervous System (CNS)
API Technology
Synthetic
Dose Form
Oral Solids
Available Regulatory Filing
USA
Europe
Innovator Brand (USA)
Saphris
Mechanism of Action
The mechanism of action of asenapine, in schizophrenia and bipolar I disorder, is unknown. It has been suggested that the efficacy of asenapine in schizophrenia could be mediated through a combination of antagonist activity at D2 and 5-HT2A receptors.
Indication
SAPHRIS is an atypical antipsychotic indicated for :
- Schizophrenia in adults
- Bipolar I disorder
- Acute monotherapy treatment of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age
- Adjunctive treatment to lithium or valproate in adults
- Maintenance monotherapy treatment in adults”